Skin Care, Skin Lesions
Conditions
Keywords
effectiveness, Contact test
Brief summary
This study was designed with the objective of evaluating the protection potential provided by the experimental product EF192B by evaluating its barrier formation capacity. Once its ability to form a barrier is confirmed, EF192B ability to protect against small skin injuries, such as small cuts, bruises, blisters and cracks is confirmed. The barrier formation also guarantees protection against the formation of calluses.
Interventions
DEVICEEF192B
EF192B will be applied after the tape strriping procedure and will be reapplied after 12 hours.
Sponsors
Eurofarma Laboratorios S.A.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
Yes
Inclusion criteria
* Age between 18 and 70 years old. * Fitzpatrick skin phototype classification I to IV. * Presence of intact skin in the test region (right forearm and left forearm for selected participants). * Agreement to adhere to the study procedures and requirements and attend the institute on the days and times determined for the assessments. * Signing of the Informed Consent Form (ICF) and the Image Disclosure Consent Form (IDCF) before carrying out any study procedure.
Exclusion criteria
* Diagnosis of skin diseases such as vitiligo, psoriasis, atopic dermatitis. * Diagnosis of immunological insufficiency. * Use of systemic corticosteroids or immunosuppressants. * Diagnosis of type 1 diabetes mellitus or insulin-dependent diabetes or presence of complications resulting from diabetes (such as retinopathy, nephropathy, neuropathy), presence of diabetes-related dermatoses (such as plantar ulcers, lipoid necrobiosis, granuloma annulare, opportunistic infections), history of episodes of hypoglycemia, diabetic ketoacidosis and/or hyperosmolar coma. * History of reaction to liquid dressings. * Known hypersensitivity to any ingredients of investigational product formulation. * Other diseases or use of drugs that may directly interfere with the study or put the research participant's health at risk. * Presence of any serious or uncontrolled diseases, at the investigator's discretion. * Pregnancy or lactation. * Participation in a clinical research protocol in the last 12 months, unless, at the investigator's discretion, their participation in the study may result in direct benefit to the participant. * Presence of any conditions that, at the investigator's discretion, make the participant unable to participate in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Evaluate the effect of EF192B on the curative effect in the protection of small skin lesions through the formation of a barrier, showing its superiority versus no treatment (control) through transepidermal water loss 12 hours after its administration. | 12 hours |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Efficacy of the EF192B in barrier formation, showing its superiority versus no treatment (control) through transepidermal water loss 12 hours after its administration. | 12 hours | — |
| Evaluate the efficacy of EF192B barrier formation through the range of transepidermal water loss 3 minutes, 6 hours, and 24 hours after its administration | 24 hours | Evaluation of barrier formation through transepidermal water loss range 3 (±1) minutes, 6 hours (± 10 minutes), and 24 hours (± 30 minutes) after the end of tape stripping versus the measurement obtained immediately after tape stripping (TEWL0) |
| Evaluate the efficacy of EF192B barrier formation through the range of corneometry 3 minutes, 6 hours, 12 hours, and 24 hours after its administration | 24 hours | Evaluation of barrier formation through corneometry range 3 (± 1) minutes, 6 hours (± 10 minutes), 12 hours (± 20 minutes), and 24 hours (± 30 minutes) after the end of tape stripping versus the measurement obtained immediately after tape stripping |
| Evaluate EF192B water resistance after four washes | 12 hours | Water resistance as assessed by the average range of color change to activated charcoal pigment one (01), two (02), three (03), and four (04) washes after administration of the investigational product |
Countries
Brazil
Contacts
Primary ContactGleyce Lima
Backup ContactLuiza Terranova
Outcome results
None listed